Aziltan40 mg Tablet 40 mg
Azilsartan Medoxomil
Category: Tablet
Manufacturer: Opsonin Pharma Limited
Allopathic
MFG. Licence No. Biological
012
MFG. Licence No. Non-Biological
080
Address
Rupatali,
Medicine Selling service is not available yet.
Related Medicines
Uses of Aziltan40 mg Tablet:
- Hypertension (high blood pressure)
- Heart failure
- Prevention of heart attack and stroke
Hypertension, alone or in combination w/ other antihypertensive agents.
Hypersensitivity. Pregnancy.
Angiotensin-ll receptor blocker
Azilsartan Medoxomil, a prodrug, is hydrolyzed to Azilsartan in the gastrointestinal tract during absorption. Azilsartan is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.
How to use
Azilsartan Medoxomil:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.
Azilsartan Medoxomil may be taken with or without food, but it is better to take it at a fixed time.
Administration:
May be taken with or without food.
Adult Dose:
Adult: Initially 40 mg once daily. May be increased to a max of 80 mg once daily as necessary.
Elderly: No dose adjustment is necessary in elderly patients
Renal Dose:
Renal Impairment
No dose adjustment is required with mild-to-severe renal impairment or end-stage renal disease.
Patients with moderate-to-severe renal impairment are more likely to report high serum creatinine values.
Reversibly increases serum conc & toxicity of lithium; attenuated antihypertensive effects & risk of worsening of renal function may occur w/ NSAIDs. Hyperkalemia w/ K-sparing diuretics & K supplements.
Hypersensitivity. Pregnancy.
Common
- Dizziness
- Muscle damage
- Diarrhea
1-10%
Diarrhea (2%)
<1%
Nausea,Asthenia,Fatigue,Muscle spasm,Dizziness,Postural hypotension,Cough
Pregnancy Category D. The risk to the fetus increases if Azilsartan Medoxomil is administered during the second or third trimesters of pregnancy. It is not known whether Azilsartan Medoxomil is excreted in human milk, as many drugs are excreted in human milk and because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Precaution:
Correct vol or salt depletion prior to administration. Renal (moderate to severe) & hepatic (severe) impairment. Pregnancy (1st trimester) & lactation. Childn <18 yr.
Monitor serum K in patients taking K-sparing diuretics, salt substitutes containing K & drugs that increase K levels (eg heparin) & creatinine levels in patients w/ renal impairment & type 2 DM. Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy.
Lactation: unknown whether distributed in breast milk, decide on alternate antihypertensive therapy or do not breastfeed
Limited data are available related to overdose in humans. In the event of and overdose, supportive therapy should be instituted as dictated by the patient’s clinical status. Azilsartan is not dialyzable.
keep in a dry place away from light and heat. Keep out of the reach of children.
Angiotensin-ll receptor blocker
Angiotensin II blocker; displaces angiotensin II from AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water absorption, and hypertrophic responses.
May induce more complete inhibition of renin-angiotensin system compared with ACE inhibitors; does not affect response to bradykinin.
Inhibits the pressor effects of an angiotensin II infusion in a dose-related manner.
Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)
Samm Care